Zhou and colleagues investigated the use of iPSC-ECs derived from patients with anti-complement factor H autoantibody-associated atypical hemolytic uremic syndrome (aHUS) [39], an acquired autoimmune disease, with a high genetic predisposition, caused by dysregulation of the complement system [40]. The gene discussed is CFH; the disease is atypical hemolytic-uremic syndrome.